Loading clinical trials...
Loading clinical trials...
The investigators will test whether hypotonic (diluted) remodulin solution causes less pain than the eutonic (undiluted) solution supplied by the manufacturer.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Jewish General Hospital
Montreal, Quebec, Canada
Start Date
July 1, 2012
Primary Completion Date
February 28, 2019
Completion Date
February 28, 2019
Last Updated
March 3, 2020
HypotonicTreprostinil Solution
DRUG
Eutonic Treprostinil Solution
DRUG
Lead Sponsor
Jewish General Hospital
NCT07218029
NCT06649110
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06481852